Ralph Lipp, Ph.D., Vice President and Chief Scientific Officer at Noven Pharmaceuticals, Inc., leads all Research and Development efforts for Noven’s transdermal drug delivery programs and related product development activities. He has more than 25 years of experience in leadership positions in the biopharmaceutical sector. Before joining Noven Ralph founded Lipp Life Sciences LLC, served as Vice President Pharmaceutical Sciences R&D at Eli Lilly and Company, and as Head of Pharmaceutical Development at Schering AG. He holds a degree in Pharmacy from Johannes Gutenberg Universität, Mainz, Germany and obtained a Ph.D. in Medicinal Chemistry as well as a Habilitation for Pharmaceutical Technology from Freie Universität Berlin, Germany. Ralph graduated from the International Executive Program at INSEAD, Fontainebleau, France and from the Advanced Management Program at Harvard Business School, Cambridge, MA, USA. His scientific contributions comprise over 140 publications, including more than 20 patents, covering five marketed medicines including one transdermal patch.